Novel directions in neoadjuvant therapy for pancreas adenocarcinoma

References

• National Cancer Institute. SEER stat fact sheets: pancreas cancer. Surveillance, epidemiology, and end results program [electronic] 2014. Available from: http://seer.cancer.gov/statfacts/html/pancreas.html
   Google Scholar
• Colon Cancer Treatment (PDQ) Health Professional Version. PDQ Cancer Information Summaries. 2014 June 5 2014. Available from: www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032814/
   Google Scholar
• Hishinuma S, Ogata Y, Tomikawa M, et al. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 2006;10(4):511-18
   PubMed Web of Science ®Google Scholar
• Belli C, Cereda S, Anand S, Reni M. Neoadjuvant therapy in resectable pancreatic cancer: a critical review. Cancer Treat Rev 2013;39(5):518-24
   PubMed Web of Science ®Google Scholar
• Cooper AB, Tzeng CW, Katz MH. Treatment of borderline resectable pancreatic cancer. Curr Treat Options Oncol 2013;14(3):293-310
   PubMed Web of Science ®Google Scholar
• Papavasiliou P, Chun YS, Hoffman JP. How to define and manage borderline resectable pancreatic cancer. Surg Clin North Am 2013;93(3):663-74
   PubMed Web of Science ®Google Scholar
• Kelly KJ, Winslow E, Kooby D, et al. Vein involvement during pancreaticoduodenectomy: is there a need for redefinition of ‘borderline resectable disease’? J Gastrointest Surg 2013;17(7):1209-17; discussion 1217
   PubMed Web of Science ®Google Scholar
• He J, Page AJ, Weiss M, et al. Management of borderline and locally advanced pancreatic cancer: where do we stand? World J Gastroenterol 2014;20(9):2255-66
   PubMed Web of Science ®Google Scholar
• Kang CM, Hwang HK, Choi SH, Lee WJ. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer. Surg Oncol 2013;22(2):123-31
   PubMed Web of Science ®Google Scholar
• Halperin DM, Varadhachary GR. Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter? Curr Oncol Rep 2014;16(2):366
   PubMed Web of Science ®Google Scholar
• Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006;13(8):1035-46
   PubMed Web of Science ®Google Scholar
• Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008;206(5):833-46; discussion 846-8
   PubMed Web of Science ®Google Scholar
• Tzeng CW, Fleming JB, Lee JE, et al. Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol 2012;19(6):2045-53
   PubMed Web of Science ®Google Scholar
• Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009;16(7):1727-33
   PubMed Web of Science ®Google Scholar
• Chun YS, Milestone BN, Watson JC, et al. Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol 2010;17(11):2832-8
   PubMed Web of Science ®Google Scholar
• Katz MH, Marsh R, Herman JM, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013;20(8):2787-95
   PubMed Web of Science ®Google Scholar
• Tempero MA, Malafa MP, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2014;12(8):1083-93
   PubMed Web of Science ®Google Scholar
• Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120(8):899-903
   PubMed Web of Science ®Google Scholar
• O’Reilly EM. Adjuvant therapy for pancreas adenocarcinoma. J Surg Oncol 2013;107(1):78-85
   PubMed Web of Science ®Google Scholar
• Antoniou G, Kountourakis P, Papadimitriou K, et al. Adjuvant therapy for resectable pancreatic adenocarcinoma: review of the current treatment approaches and future directions. Cancer Treat Rev 2014;40(1):78-85
   PubMed Web of Science ®Google Scholar
• Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230(6):776-82; discussion 782-4
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350(12):1200-10
   PubMed Web of Science ®Google Scholar
• Burris HA3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15(6):2403-13
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297(3):267-77
   PubMed Web of Science ®Google Scholar
• Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013;310(14):1473-81
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;10:1073-81
   PubMed Web of Science ®Google Scholar
• Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 2011;18(5):1319-26
   PubMed Web of Science ®Google Scholar
• Berger AC, Winter K, Hoffman JP, et al. Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 </=90 U/mL and comparison to the CONKO-001 trial. Int J Radiat Oncol Biol Phys 2012;3):e291-7
   Google Scholar
• Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 2013;31(13):1640-8
   PubMed Web of Science ®Google Scholar
• Fukutomi A, Uesaka K, Boku N, et al. JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol 31 2013;( Suppl; Abstract 4008) 2013 ASCO Annual Meeting 2013
   PubMedGoogle Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817-25
   PubMed Web of Science ®Google Scholar
• Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 2013;31(1):23-9
   PubMed Web of Science ®Google Scholar
• Oikonomopoulos GM, Syrigos KN, Skoura E, Saif MW. FOLFIRINOX: From the ACCORD Study to 2014. JOP 2014;15(2):103-5
   PubMedGoogle Scholar
• Chandhok NS, Saif MW. Updates on the use of neoadjuvant therapy in borderline resectable pancreatic cancer. JOP 2014;15(2):91-4
   PubMedGoogle Scholar
• Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01526135
   Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369(18):1691-703
   PubMed Web of Science ®Google Scholar
• Nab-paclitaxel and gemcitabine vs gemcitabine alone as adjuvant therapy for patients with resected pancreatic cancer (the ‘Apact’ Study) (apact). Available from: https://clinicaltrials.gov/ct2/show/NCT01964430
   Google Scholar
• Randomized multicenter Phase II/III study with adjuvant gemcitabine Versus Neoadjuvant/ Adjuvant FOLFIRINOX for resectable pancreas carcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02172976
   Google Scholar
• A pilot study of pre- and post-surgery chemotherapy with mFOLFIRINOX in localized, resectable pancreatic adenocarcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01660711
   Google Scholar
• Gemcitabine hydrochloride with or without erlotinib hydrochloride followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in treating patients with pancreatic cancer that has been removed by surgery. Available from: https://clinicaltrials.gov/ct2/show/NCT01013649
   Google Scholar
• Ishikawa O, Ohigashi H, Imaoka S, et al. Is the long-term survival rate improved by preoperative irradiation prior to Whipple’s procedure for adenocarcinoma of the pancreatic head? Arch Surg 1994;129(10):1075-80
   PubMedGoogle Scholar
• Staley CA, Lee JE, Cleary KR, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 1996;171(1):118-24; discussion 124-5
   PubMed Web of Science ®Google Scholar
• Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997;15(3):928-37
   PubMed Web of Science ®Google Scholar
• Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26(21):3496-502
   PubMed Web of Science ®Google Scholar
• Talamonti MS, Small WJr, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006;13(2):150-8
   PubMed Web of Science ®Google Scholar
• Stessin AM, Meyer JE, Sherr DL. Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. Int J Radiat Oncol Biol Phys 2008;72(4):1128-33
   PubMed Web of Science ®Google Scholar
• Yamada S, Fujii T, Sugimoto H, et al. Aggressive surgery for borderline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines. Pancreas 2013;42(6):1004-10
   PubMed Web of Science ®Google Scholar
• Network, N.C.C., NCCN Guidelines Version 2.2014 Pancreatic Adenocarcinoma. NCCN Guidelines For Treatment of Cancer by Site, 2014
   Google Scholar
• Xu CP, Xue XJ, Liang N, et al. Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2014;140(4):549-59
   PubMed Web of Science ®Google Scholar
• O’Reilly EM, Perelshteyn A, Jarnagin WR, et al. A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma. Ann Surg 2014;260(1):142-8
   PubMed Web of Science ®Google Scholar
• Motoi F, Ishida K, Fujishima F, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol 2013;20(12):3794-801
   PubMed Web of Science ®Google Scholar
• Sahora K, Kuehrer I, Eisenhut A, et al. NeoGemOx: gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery 2011;149(3):311-20
   PubMed Web of Science ®Google Scholar
• Sahora K, Kuehrer I, Schindl M, et al. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. World J Surg 2011;35(7):1580-9
   PubMed Web of Science ®Google Scholar
• Andriulli A, Festa V, Botteri E, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol 2012;19(5):1644-62
   PubMed Web of Science ®Google Scholar
• Leone F, Gatti M, Massucco P, et al. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer 2013;119(2):277-84
   PubMed Web of Science ®Google Scholar
• Kadera BE, Sunjaya DB, Isacoff WH, et al. Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival. JAMA Surg 2014;149(2):145-53
   PubMed Web of Science ®Google Scholar
• Sho M, Akahori T, Tanaka T, et al. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. J Hepatobiliary Pancreat Sci 2013;20(2):197-205
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 2013;14(4):317-26
   PubMed Web of Science ®Google Scholar
• Gemcitabine with or without capecitabine and/or radiation therapy or gemcitabine with or without erlotinib in treating patients with locally advanced pancreatic cancer that cannot be removed by surgery. Available from: https://clinicaltrials.gov/ct2/show/NCT00634725
   Google Scholar
• Hammel P, Huguet F, Van Laethem JL, et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. J Clin Oncol 2013; (Suppl; Abstract LBA4003)
   Google Scholar
• Boone BA, Steve J, Krasinskas AM, et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol 2013;108(4):236-41
   PubMed Web of Science ®Google Scholar
• Faris JE, Blaszkowsky LS, McDermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist 2013;18(5):543-8
   PubMed Web of Science ®Google Scholar
• Christians KK, Tsai S, Mahmoud A, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist 2014;19(3):266-74
   PubMed Web of Science ®Google Scholar
• NEOadjuvant Gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer (NEOPAC). Available from: https://clinicaltrials.gov/ct2/show/NCT01521702
   Google Scholar
• Heinrich S, Pestalozzi B, Lesurtel M, et al. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer 2011;11:346
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29(34):4548-54
   PubMed Web of Science ®Google Scholar
• Study of gemcitabine and abraxane to treat potentially operable pancreatic cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01298011
   Google Scholar
• Neoadjuvant plus adjuvant or only adjuvant nab- paclitaxel plus gemcitabine for resectable pancreatic cancer (NEONAX). Available from: https://clinicaltrials.gov/ct2/show/NCT02047513
   Google Scholar
• Gemcitabine with abraxane and other investigational therapies in neoadjuvant treatment of pancreatic adenocarcinoma (GAIN-1). Available from: https://clinicaltrials.gov/ct2/show/NCT01470417
   Google Scholar
• A Phase 2 trial of gemcitabine plus nab-paclitaxel with or without fg-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT02210559
   Google Scholar
• Chemotherapy and radiation therapy before surgery followed by gemcitabine in treating patients with pancreatic cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01821612
   Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54
   PubMed Web of Science ®Google Scholar
• Shibuya KC, Goel VK, Xiong W, et al. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. PLoS One 2014;9(5):e96565
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369(2):122-33
   PubMed Web of Science ®Google Scholar
• A Phase 1/2, open-label study of nivolumab monotherapy or nivolumab combined with ipilimumab in subjects with advanced or metastatic solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT01928394
   Google Scholar
• Le DT, Brockstedt DG, Nir-Paz R, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 2012;18(3):858-68
   PubMed Web of Science ®Google Scholar
• Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 2011;253(2):328-35
   PubMed Web of Science ®Google Scholar
• Le DT, Jaffee EM. Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J Natl Compr Canc Netw 2013;11(7):766-72
   PubMed Web of Science ®Google Scholar
• Safety and efficacy of combination listeria/gvax pancreas vaccine in the pancreatic cancer setting (ECLIPSE). Available from: https://clinicaltrials.gov/ct2/show/NCT02004262
   Google Scholar
• Vaccine therapy with or without cyclophosphamide in treating patients undergoing chemotherapy and radiation therapy for stage i or stage ii pancreatic cancer that can be removed by surgery. Available from: https://clinicaltrials.gov/ct2/show/NCT00727441
   Google Scholar
• Saif MW. Adjuvant therapy of pancreatic cancer: beyond gemcitabine. Highlights from the ‘2011 ASCO Gastrointestinal Cancers Symposium’. San Francisco, CA, USA. January 20-22, 2011. JOP 2011;12(2):106-9
   PubMedGoogle Scholar
• Hardacre JM, Mulcahy M, Small W, et al. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg 2013;17(1):94-100. discussion 100; 1
   PubMed Web of Science ®Google Scholar
• Immunotherapy study for surgically resected pancreatic cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01072981
   Google Scholar
• Immunotherapy study in borderline resectable or locally advanced unresectable pancreatic cancer (PILLAR). Available from: https://clinicaltrials.gov/ct2/show/NCT01836432
   Google Scholar
• Vonderheide RH, Bajor DL, Winograd R, et al. CD40 immunotherapy for pancreatic cancer. Cancer Immunol Immunother 2013;62(5):949-54
   PubMed Web of Science ®Google Scholar
• He S, Zhao H, Fei M, et al. Expression of the co-signaling molecules CD40-CD40L and their growth inhibitory effect on pancreatic cancer in vitro. Oncol Rep 2012;28(1):262-8
   PubMed Web of Science ®Google Scholar
• Beatty GL, Torigian DA, Chiorean EG, et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res 2013;19(22):6286-95
   PubMed Web of Science ®Google Scholar
• Phase 1 Study of preoperative gemcitabine plus cp-870, 893 followed by addition of cp-870,893 to standard -of-care adjuvant chemoradiation for patients with newly diagnosed resectable pancreatic carcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01456585
   Google Scholar
• Rahma OE, Hamilton JM, Wojtowicz M, et al. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med 2014;12:55
   PubMed Web of Science ®Google Scholar
• Toubaji A, Achtar M, Provenzano M, et al. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother 2008;57(9):1413-20
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Chapman PB, Feilchenfeldt J, et al. Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol 2011;34(3):321-5
   PubMed Web of Science ®Google Scholar
• Nab-paclitaxel combined with gemcitabine as adjuvant therapy for pancreatic cancer after curative resection (No). Available from: https://clinicaltrials.gov/ct2/show/NCT02023021
   Google Scholar
• Landry J, Catalano PJ, Staley C, et al. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 2010;101(7):587-92
   PubMed Web of Science ®Google Scholar
• Heinrich S, Pestalozzi BC, Schäfer M, et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26(15):2526-31
   PubMed Web of Science ®Google Scholar
• Palmer DH, Stocken DD, Hewitt H, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007;14(7):2088-96
   PubMed Web of Science ®Google Scholar
• Mornex F, Girard N, Scoazec JY, et al. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: the French SFRO-FFCD 97-04 Phase II trial. Int J Radiat Oncol Biol Phys 2006;65(5):1471-8
   PubMed Web of Science ®Google Scholar
• Pipas JM, Barth RJJr, Zaki B, et al. Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 2005;12(12):995-1004
   PubMed Web of Science ®Google Scholar
• Lee JL, Kim SC, Kim JH, et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery 2012;152(5):851-62
   PubMed Web of Science ®Google Scholar
• Neoadjuvant treatment in resectable pancreatic cancer (NEOPA). Available from: https://www.clinicaltrials.gov/ct2/show/NCT01900327
   Google Scholar
• Neoadjuvant FOLFIRINOX regimen in patients with non-metastatic pancrease cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01771146
   Google Scholar
• Gemcitabine, cisplatin, epirubicin, and capecitabine in treating patients with Stage I-II resectable pancreatic cancer (PACT-15). Available from: https://clinicaltrials.gov/ct2/show/NCT01150630
   Google Scholar
• A Phase II study of neoadjuvant FOLFIRINOX. Available from: https://clinicaltrials.gov/ct2/show/NCT02178709
   Google Scholar
• Efficacy and safety of a neoadjuvant treatment in pancreatic cancer (GEMCAD1003). Available from: https://clinicaltrials.gov/ct2/show/NCT01389440
   Google Scholar
• Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery. Available from: https://clinicaltrials.gov/ct2/show/NCT00733746
   Google Scholar